EUVIMEDEUVIMED entdecken
Open Access

Toward Next-Gen Cell Therapy for Pediatric Patients: Neonatal Hepatocytes Tolerate Electroporation-Mediated Gene Editing and Engraft in the Liver

Justin R Gibson, Abishek Dhungana, Menam Pokhrel, Benjamin Bessah Arthur, Olumide Adebayo, Daniel Hossack, Renee N Cottle iD

The CRISPR Journal · 2026

DOI: 10.1177/25731599261430830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The CRISPR Journal, 2026. Verfasst von Justin R Gibson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, College of Engineering, Computing, and Applied Sciences, Clemson University, Clemson, South Carolina, USA. Hauptthemen laut MEDLINE: Hepatocytes, Gene Editing, Electroporation, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocyte transplantation (HTx) offers a safer, less invasive alternative to orthotopic liver transplantation for inherited metabolic liver diseases, especially in high-risk pediatric patients. Combining HTx with ex vivo gene editing is a promising autologous therapeutic strategy using the patient’s cells. We investigated the feasibility of this approach by applying CRISPR-Cas9 gene knock-out to neonatal mouse hepatocytes and comparing their engraftment potential with that of mature adult cells in the Fah −/− mouse model of hereditary tyrosinemia type I (HT1). Electroporation-mediated gene editing did not significantly impair the ability of neonatal hepatocytes to engraft in vivo . Quantitative histological analysis revealed comparable liver repopulation levels between recipients of gene-edited neonatal cells and adult cells after hepatoxicity-mediated selection, providing a benchmark for electroporation-mediated gene editing in neonatal hepatocytes, and supporting the development of genetically corrected neonatal hepatocyte products as a crucial long-term or bridge-to-transplant therapeutic strategy for pediatric liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatocytesGene EditingElectroporationCell- and Tissue-Based TherapyAnimalsMiceLiverHumansTyrosinemiasAnimals, NewbornCRISPR-Cas SystemsMice, KnockoutDisease Models, AnimalHydrolases

Substanzen

fumarylacetoacetaseHydrolases

Autor:innen und Institutionen

  • Department of Bioengineering, College of Engineering, Computing, and Applied Sciences, Clemson University, Clemson, South Carolina, USA.
  • Institute for Human Genetics, Clemson University, Greenwood, South Carolina, USA.

ORCID-Profile: Renee N Cottle

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Gibson, J. R., Dhungana, A., Pokhrel, M., Arthur, B. B., Adebayo, O., Hossack, D., & Cottle, R. N. (2026). Toward Next-Gen Cell Therapy for Pediatric Patients: Neonatal Hepatocytes Tolerate Electroporation-Mediated Gene Editing and Engraft in the Liver. The CRISPR Journal. https://doi.org/10.1177/25731599261430830

Vancouver

Gibson JR, Dhungana A, Pokhrel M, Arthur BB, Adebayo O, Hossack D, et al. Toward Next-Gen Cell Therapy for Pediatric Patients: Neonatal Hepatocytes Tolerate Electroporation-Mediated Gene Editing and Engraft in the Liver. The CRISPR Journal. 2026. doi:10.1177/25731599261430830

BibTeX
@article{Gibson2026,
  author = {Gibson, Justin R and Dhungana, Abishek and Pokhrel, Menam and Arthur, Benjamin Bessah and Adebayo, Olumide and Hossack, Daniel and Cottle, Renee N},
  title = {Toward Next-Gen Cell Therapy for Pediatric Patients: Neonatal Hepatocytes Tolerate Electroporation-Mediated Gene Editing and Engraft in the Liver},
  journal = {The CRISPR Journal},
  year = {2026},
  doi = {10.1177/25731599261430830}
}
Kostenlos starten →